Orexigen(R) Therapeutics to Speak at RBC Capital Markets Investor Conference Panel

Monday, December 8, 2008 General News J E 4
SAN DIEGO, Dec. 8 Orexigen(R) Therapeutics, Inc.(Nasdaq: OREX), a biopharmaceutical company focused on the treatment ofobesity, today announced that the Company will be speaking at the RBC CapitalMarkets Investor Conference. The presentation will be a panel format, titled"Shrinking the Obesity Epidemic." The details are as follows:

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on thetreatment of obesity. The Company's lead combination product candidates areContrave, which is in Phase 3 clinical trials, and Empatic, which is in thelater stages of Phase 2 clinical development. Each product candidate isdesigned to act on a specific group of neurons in the central nervous systemwith the goal of achieving appetite suppression and sustained weight loss.Further information about the company can be found at Wednesday, December 10 Time: 11:00 a.m. - 11:55 a.m. Eastern Location: Westin Times Square Hotel, New York

SOURCE Orexigen Therapeutics, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Expresso Fitness(R) Receives Additional $14 Millio...
Genomic Health Announces Appointment of Ginger Gra...